KR20240070634A - Tyk2 억제제에 대한 반응성을 결정하는 방법 - Google Patents

Tyk2 억제제에 대한 반응성을 결정하는 방법 Download PDF

Info

Publication number
KR20240070634A
KR20240070634A KR1020247013861A KR20247013861A KR20240070634A KR 20240070634 A KR20240070634 A KR 20240070634A KR 1020247013861 A KR1020247013861 A KR 1020247013861A KR 20247013861 A KR20247013861 A KR 20247013861A KR 20240070634 A KR20240070634 A KR 20240070634A
Authority
KR
South Korea
Prior art keywords
baseline
treatment
levels
ducravasitinib
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247013861A
Other languages
English (en)
Korean (ko)
Inventor
옌화 후
루 가오
이안 맥쿼리 캐트렛
시앙 궈
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20240070634A publication Critical patent/KR20240070634A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247013861A 2021-09-30 2022-09-29 Tyk2 억제제에 대한 반응성을 결정하는 방법 Pending KR20240070634A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163250735P 2021-09-30 2021-09-30
US63/250,735 2021-09-30
US202163257407P 2021-10-19 2021-10-19
US63/257,407 2021-10-19
US202263330308P 2022-04-12 2022-04-12
US63/330,308 2022-04-12
PCT/US2022/045187 WO2023055901A2 (en) 2021-09-30 2022-09-29 Methods for determining responsiveness to tyk2 inhibitors

Publications (1)

Publication Number Publication Date
KR20240070634A true KR20240070634A (ko) 2024-05-21

Family

ID=84359787

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013861A Pending KR20240070634A (ko) 2021-09-30 2022-09-29 Tyk2 억제제에 대한 반응성을 결정하는 방법

Country Status (5)

Country Link
US (1) US20240390369A1 (https=)
EP (1) EP4408527A2 (https=)
JP (1) JP2024535467A (https=)
KR (1) KR20240070634A (https=)
WO (1) WO2023055901A2 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
TW201217387A (en) 2010-09-15 2012-05-01 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use
EP2818473A4 (en) 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
WO2013146963A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
BR112014029310A2 (pt) 2012-05-24 2018-06-26 Cellzome Ltd análogos da pirimidina heterocíclica como inibidores da tyk2
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
JPWO2015016206A1 (ja) 2013-07-30 2017-03-02 武田薬品工業株式会社 複素環化合物
MX369974B (es) 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
TWI707852B (zh) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba

Also Published As

Publication number Publication date
US20240390369A1 (en) 2024-11-28
WO2023055901A2 (en) 2023-04-06
EP4408527A2 (en) 2024-08-07
JP2024535467A (ja) 2024-09-30
WO2023055901A3 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
Enache et al. Peripheral immune markers and antipsychotic non-response in psychosis
Kim et al. Asthma biomarkers in the age of biologics
Calabrò et al. CRP and the risk of atherosclerotic events
Hawkins et al. The IL6R variation Asp358Ala is a potential modifier of lung function in subjects with asthma
Möbus et al. Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis
Romão et al. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?
Panoulas et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking
CN107121555B (zh) 评估肾结构改变和结果
AU2016349113A1 (en) Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
Boman et al. Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
Murata et al. Effects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression
Simac et al. Serum catestatin levels in patients with rheumatoid arthritis
Giannini et al. Sarcopenia assessed by DXA and hand-grip dynamometer: a potential marker of damage, disability and myokines imbalance in inflammatory myopathies
Ye et al. Adrenomedullin expression is associated with the severity and poor prognosis of interstitial lung disease in dermatomyositis patients
Nguyen et al. Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis
Falcone et al. Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease
Nenke et al. Reduced corticosteroid‐binding globulin cleavage in active rheumatoid arthritis
US20240390369A1 (en) Methods for determining responsiveness to tyk2 inhibitors
CA3045138A1 (en) Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis
JP6687391B2 (ja) リウマチ性関節炎（ｒａ）の存在を決定するためのサンプルの測定方法
DK2931920T3 (en) BIOMARKERS FOR INFLAMMATORY ASTMPHENotypes AND TREATMENT RESPONSE
CN118414546A (zh) 用于确定对tyk2抑制剂的反应性的方法
Takekawa et al. Lower fractional exhaled nitric oxide levels are associated with depressive symptom in males: A population-based cross-sectional study
CN104105967B (zh) 生腱蛋白c及其在类风湿关节炎的用途
Cremer et al. Prognostic significance of somatic mutations in myeloid cells of men with chronic heart failure–interaction between loss of Y chromosome and clonal hematopoiesis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000